| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-016 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 会议由公司董事长池骋先生主持，监事、高管列席会议。本次会议的召集、召 开符合《中华人民共和国公司法》等法律、法规和《公司章程》的有关规定。 二、董事会会议审议情况 经各位董事认真审议，会议形成了如下决议： 浙江东亚药业股份有限公司 第四届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江东亚药业股份有限公司（以下简称"公司"）第四届董事会第七次会议于 2025 年 4 月 28 日（星期一）在浙江省台州市临海市台州湾经济技术开发区东海第 五大道 21 号二楼会议室五以现场结合通讯的方式召开。本次会议通知于 2025 年 4 月 18 日以邮件的方式发出。本次会议应出席董事 7 人，实际出席董事 7 人。 （一）审议通过《关于 2024 年度总经理工作报告的议案》 表决情况：同意 7 票，反对 ...

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-018 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 关于 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江东亚药业股份有限公司（以下简称"公司"）2024 年度拟不进行利润 分配，亦不进行资本公积金转增股本和其他形式的分配。 公司 2024 年度利润分配预案已经公司第四届董事会第七次会议和第四 届监事会第六次会议审议通过，尚需提交公司 2024 年年度股东大会审议批准。 公司不触及《上海证券交易所股票上市规则（2024 年 4 月修订）》（以下 简称"《股票上市规则》"）第 9.8.1 条第一款第（八）项规定的可能被实施其他风 险警示的情形。 一、利润分配预案内容 （一）利润分配预案的具体内容 经中汇会计师事务所（特殊普通合伙）审计，公司 2024 年度合并报表实现 归属于上市公司股东的净利润为人民币-10,066 ...

浙江东亚药业股份有限公司 内部控制审计报告 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 www.zhcpa.cn Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 内部控制审计报告 中汇会审[2025]6493号 浙江东亚药业股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了浙江东亚药业股份有限公司(以下简称东亚药业公司)2024年12月31日的 财务报告内部控制的有效性。 一、企业对内部控制的责任 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，东亚药业公司于2024年12月31日按照《企业内部控制 ...

2024年度持续督导年度报告书 经中国证券监督管理委员会（以下简称"中国证监会"）"证监许可〔2023〕 1165 号文"核准，浙江东亚药业股份有限公司（以下简称"东亚药业"或"公司"） 于 2023 年向不特定对象发行可转换公司债券 690 万张，每张面值为人民币 100.00 元，募集资金总额为人民币 69,000 万元（以下简称"本次发行"）。东兴证券股份 有限公司（以下简称"东兴证券"或"保荐机构"）作为东亚药业本次发行的保荐 机构。 东兴证券股份有限公司 关于浙江东亚药业股份有限公司 东兴证券根据《证券发行上市保荐业务管理办法》、《上海证券交易所股票上市 规则》、《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》、 《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等相关法规和规 范性文件的要求，对东亚药业进行了持续督导，现对 2024 年度持续督导工作汇报 如下： 一、持续督导工作情况 东兴证券作为东亚药业本次发行的保荐机构，针对东亚药业具体情况确定了持 续督导的内容和重点，通过日常沟通、定期回访、尽职调查等方式对东亚药业进行 了日常的持续督导，开展了以下相关工作： ...

为满足东亚药业及合并报表范围内子公司经营和业务发展需求，保证子公司 生产经营活动的顺利开展，在确保规范运作和风险可控的前提下，公司拟向合并 报表范围内子公司提供总额不超过 22,000 万元的担保，提供担保的形式包括但 不限于信用担保（含一般保证、连带责任保证等）、抵押担保、质押担保或多种 担保方式相结合等形式。 （二）履行的内部决策程序 公司于 2025 年 4 月 28 日召开第四届董事会第七次会议，审议通过了《关 于 2025 年度对外担保额度预计的议案》，预计担保额度的有效期为自公司股东 大会审议通过之日起 12 个月内有效，并提请股东大会授权公司董事长或其授权 代表在上述担保总额范围内确定各项融资业务方式及金额、担保方与被担保方、 担保金额、调剂额度和具体担保内容等相关事宜，并签署相关各项法律文件，公 司不再另行召开董事会、股东大会进行审议。本次担保额度预计事项尚需提交公 司股东大会审议。 东兴证券股份有限公司关于 浙江东亚药业股份有限公司 2025年度对外担保额度预计的核查意见 东兴证券股份有限公司（以下简称"东兴证券"或"保荐机构"）作为浙江 东亚药业股份有限公司（以下简称"东亚药业"、"上市公 ...

浙江东亚药业股份有限公司 2024 年度审计报告 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel. 0571-88879999 Fax.0571-88879000 www.zhcpa.cn 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn） 报告编码:浙2521 the state of the state of the state of the station of the subject of the subject of the subject of the subject of the subject o | > | | --- | 求 | | 页 次 | | --- | --- | | 一、审计报告 | 1-6 | | 二、财务报表 | 7-18 | | (一) 合并资产负债表 | 7-8 | | (二) 合并利润表 | ...

Financial Performance - The company's operating revenue for 2024 was CNY 1,198,238,535.39, a decrease of 11.66% compared to CNY 1,356,448,097.16 in 2023[26]. - The net profit attributable to shareholders for 2024 was CNY -100,660,051.84, representing a decline of 183.02% from CNY 121,249,399.50 in 2023[26]. - Basic earnings per share for 2024 were CNY -0.90, a significant drop of 184.11% compared to CNY 1.07 in 2023[27]. - The weighted average return on equity decreased to -5.19% in 2024, down 11.49 percentage points from 6.30% in 2023[27]. - The company reported a net cash flow from operating activities of CNY -156,549,765.40 for 2024, compared to CNY -84,061,904.21 in 2023[26]. - The company achieved operating revenue of 1,198.24 million RMB, a year-on-year decrease of 11.66%[35]. - The net profit attributable to shareholders was -100.66 million RMB, a year-on-year decrease of 183.02%[35]. - The gross margin improved by 1.12% to 27.76% due to enhanced management and cost control measures[36]. Research and Development - Research and development expenses increased significantly as the company pursued an integrated development strategy for raw material drugs[28]. - R&D investment for 2024 was 138.88 million RMB, accounting for 11.59% of operating revenue[38]. - The company has 8 formulation applications accepted by the National Medical Products Administration, with over 10 more planned for submission[36]. - The company established a synthetic biology research platform to enhance its product pipeline and competitiveness[39]. - The company is focusing on expanding its product portfolio in the anti-infection and anti-fungal categories to enhance market presence[111]. - The company plans to continue its investment in R&D to support the development of new drugs and improve existing formulations[112]. - The total R&D investment for 2024 was CNY 138.88 million, representing a 69.14% increase year-over-year and accounting for 11.59% of total revenue[112]. Market Position and Strategy - The company is positioned as a WHO-recommended supplier for Levofloxacin, facilitating its global market expansion[40]. - The company has established a competitive advantage in the production of 7-ACCA, a key intermediate for cephalexin, being one of the few in the industry capable of synthesizing it from penicillin[62]. - The company is actively extending its product line into ceftazidime and cefoperazone, with submissions for CDE approval already made[62]. - The company is focusing on expanding its integrated strategy of "raw materials + formulations" through the construction of convertible bond projects[64]. - The company aims to develop into an internationally leading pharmaceutical enterprise specializing in high-end raw materials, intermediates, and formulations[142]. - The company plans to launch new products in the next three to five years, focusing on high-end markets and obtaining relevant registrations[141]. Corporate Governance - The board of directors and supervisory board members have guaranteed the authenticity and completeness of the annual report[5]. - The company has established a robust internal control system to manage operational risks, consisting of decision-making, operational, and execution layers[165]. - The company adheres to strict information disclosure regulations, ensuring timely and accurate communication with all shareholders[164]. - The company held its first extraordinary general meeting of 2024 on April 1, where it approved a proposal to adjust the conversion price of bonds[166]. - The company plans to implement a restricted stock incentive plan in 2024, with related proposals to be discussed in upcoming shareholder meetings[167]. - The company is committed to enhancing investor relations and maintaining open communication channels with investors[164]. Risk Management - The company reported no significant risks affecting its operations during the reporting period[10]. - The company has confirmed that there are no non-operational fund occupations by controlling shareholders or related parties[10]. - The company has not faced any violations in decision-making procedures regarding external guarantees[10]. - The company faces risks from intensified market competition in the raw materials and intermediates sector, particularly from emerging competitors in China and India[153]. - Regulatory changes in the pharmaceutical industry may increase operational costs and require the company to adapt quickly to avoid performance declines[154]. Environmental and Safety Measures - The company has enhanced its safety production and environmental protection measures, leading to significant reductions in hazardous waste disposal costs and overall production costs[42]. - The company emphasizes safety production and has implemented various safety management regulations to mitigate risks associated with hazardous materials[157]. - The company has established strict environmental control systems to comply with high regulatory standards, but may face increased costs due to stricter environmental policies[156]. Employee and Management Structure - The company has a total of 1,749 employees, with 388 in the parent company and 1,361 in major subsidiaries[195]. - The employee composition includes 1,005 production personnel, 463 technical personnel, and 17 sales personnel[195]. - The company has implemented a dual salary structure consisting of basic salary and performance-based salary, with performance pay linked to annual business results[196]. - The company provides various training programs to enhance employee skills, integrating internal and external resources[198]. Financial Management - The company completed a share buyback of 2,170,103 shares for a total amount of ¥54.99 million, aimed at optimizing the equity structure and demonstrating confidence in its long-term value[42]. - The company plans to use temporarily idle funds from convertible bonds for cash management, reflecting a proactive approach to liquidity management[182]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 6.6499 million yuan[174].

Financial Performance - The company's operating revenue for Q1 2025 was ¥190,921,213.83, a decrease of 45.85% compared to ¥352,582,674.10 in the same period last year[4] - The net profit attributable to shareholders was -¥6,919,576.54, representing a decline of 128.78% from ¥24,039,198.04 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥10,505,893.27, down 151.56% from ¥20,376,579.89 in the previous year[4] - The basic earnings per share were -¥0.06, a decrease of 128.57% compared to ¥0.21 in the same period last year[5] - The diluted earnings per share were -¥0.05, down 131.25% from ¥0.16 year-on-year[5] - The weighted average return on equity was -0.37%, a decrease of 1.56 percentage points from 1.19% at the end of the previous year[5] - Total operating revenue for Q1 2025 was ¥190,921,213.83, a decrease of 46% compared to ¥352,582,674.10 in Q1 2024[17] - Net profit for Q1 2025 was a loss of ¥6,944,904.17, compared to a profit of ¥24,039,198.04 in Q1 2024, representing a significant decline[19] - Basic earnings per share for Q1 2025 were -¥0.06, compared to ¥0.21 in Q1 2024[19] Cash Flow and Liquidity - The net cash flow from operating activities was -¥134,527,926.86, compared to -¥97,089,771.88 in the same period last year, indicating a worsening cash flow situation[4] - Cash inflow from operating activities in Q1 2025 was ¥161,648,356.28, down from ¥187,462,985.54 in Q1 2024[20] - Cash paid for purchasing goods and services in Q1 2025 was ¥211,678,832.80, an increase from ¥190,711,887.65 in Q1 2024[20] - The total cash and cash equivalents at the end of the period decreased to $238.29 million from $665.96 million, reflecting a significant reduction in liquidity[21] - The company experienced a cash outflow of $250.04 million during the period, compared to a smaller outflow of $35.00 million previously, indicating a worsening cash position[21] - Cash outflow for investment activities was $245.04 million, up from $138.97 million, suggesting aggressive investment strategies[21] - The net cash flow from operating activities was -$134.53 million, compared to -$97.09 million in the previous period, indicating a decline in operational cash generation[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,485,834,743.46, a decrease of 1.99% from ¥3,556,607,162.74 at the end of the previous year[5] - The company's current assets totaled RMB 1,426,806,317.93, down from RMB 1,528,952,567.49, indicating a decrease of about 7%[14] - Cash and cash equivalents decreased significantly from RMB 513,176,766.27 to RMB 253,575,131.72, representing a decline of approximately 51%[13] - Total liabilities decreased from RMB 1,681,871,175.04 to RMB 1,614,992,526.30, reflecting a decline of about 4%[15] - The company's equity attributable to shareholders decreased from RMB 1,874,615,395.36 to RMB 1,870,746,952.45, a slight decline of around 0.2%[15] - The total liabilities and equity amounted to ¥3,485,834,743.46 as of the end of Q1 2025, a decrease from ¥3,556,607,162.74 in the previous year[16] Investments and Expenses - Research and development expenses for Q1 2025 were ¥23,009,005.87, up from ¥19,280,144.23 in Q1 2024, indicating increased investment in innovation[17] - The company reported a credit impairment loss of ¥3,330,066.74 in Q1 2025, compared to a gain of ¥4,848,150.68 in Q1 2024[18] - The company experienced a significant increase in management expenses, which rose to ¥43,208,414.35 in Q1 2025 from ¥40,657,303.31 in Q1 2024[17] Government Support and Market Conditions - The company received government subsidies amounting to ¥3,167,874.39, which were closely related to its normal operations[6] - The decrease in revenue was primarily due to reduced order demand from downstream customers for β-lactam antibiotics[7]

浙江东亚药业股份有限公司 浙江东亚药业股份有限公司 2024年度独立董事履职情况报告 本人作为浙江东亚药业股份有限公司（以下简称"公司"）的独立董事，2024 年度,本人严格按照《公司法》《证券法》《上市公司独立董事管理办法》《上海 证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号—— 规范运作》等法律、法规及《公司章程》的有关规定,本着客观、公正、独立的 原则,勤勉尽职地履行独立董事的职责和义务,积极出席相关会议,认真审议董 事会各项议案,对公司重大事项发表了独立意见,切实维护公司和公众股东的合 法权益，促进公司规范运作，充分发挥了独立董事及各专门委员会的作用。现将 本人履行独立董事职责的情况报告如下: 一、 独立董事的基本情况 (一) 个人工作履历、专业背景以及兼职情况 泰方中，男,1969年 11 月出生,毕业于浙江大学并获工学博士学位;1989 年 7 月-1996 年 8 月,任安徽省煤田地质局助理工程师:2006 年-2010 年在浙江 大学管理学院进行博士后研究;2009年-2010 年在德国弗劳恩霍夫协会软件与系 统技术研究院任客座研究员。2003年 5 月至今,任浙江工 ...

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-017 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 关于 2024 年度可转换公司债券募集资金存放与实际使用 情况的专项报告 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求（2022 年修订）》和《上海证券交易所上市公司自律 监管指引第 1 号——规范运作（2023 年 12 月修订）》《上海证券交易所股票上市 规则（2024 年 4 月修订）》等有关规定，浙江东亚药业股份有限公司（以下简称 "公司"）董事会编制了《2024 年度可转换公司债券募集资金存放与实际使用情 况的专项报告》。具体如下： 一、可转换公司债券募集资金基本情况 （一）可转换公司债券实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意浙江东亚药业股份有限公司向不特 定对象发行可转换公司债券注册的批复》（证监许可〔2023〕1165 号）核准，同 意公司向不特定对象发行可转换公司债券注册申请。截至 2023 年 7 月 ...